KIRKLAND, Wash., Dec. 11, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the second quarter fiscal 2026, which ended October 31, 2025. Financial Highlights Generated revenue of $22.6 million in Q2 FY26, an increase of 53% compared to the prior year period.Expanded gross margin to 50.6% in Q2 FY26 compared to 39.6% in the prior year period.Increased FY26 revenue guidance to $91 million, which would represent growth of 52% compared to FY25. “Kestra delivered another strong quarter of financial performance, generating revenue growth of 53% while expanding gross margin to over 50%, an important milestone for the company,” said Brian Webster, President and CEO. “We also continued to make progress on several key operational objectives, including growing the commercial organization, announcing compelling primary results from our post-approval study at the American Heart Association annual meeting, and fortifying our balance sheet with an equity offering earlier this month. As we progress on our journey to category leadership, our team remains focused on growing the wearable defibrillator market and executing on our commitments to patients and their prescribers.” Second Quarter Fiscal 2026 Financial Results Total revenue was $22.6 million, an increase of 53% compared to the prior year period. 4,696 prescriptions were written for the ASSURE® system, an increase of 54% compared to the prior year period.Revenue growth was driven by higher market share and continuing WCD market expansion. Revenue also benefited from a higher mix of in-network patients and continued improvements in revenue cycle management capabilities. Gross profit was $11.4 million compared to $5.8 million in the prior year period. Gross margin expanded to 50.6% compared to 39.6% in the prior year period, driven by volume leverage and a higher mix of in-network patients. GAAP operating expenses were $43.2 million and included $1.0 million of non-recurring costs. GAAP operating expenses were $25.0 million in the prior year period. Excluding non-recurring costs and share-based compensation expense, operating expenses were $33.5 million in Q2 FY26 compared to $23.8 million in Q2 FY25. The increase was attributable to growth in expenses related to commercial expansion and public company costs. GAAP net loss and comprehensive loss was $32.8 million compared to GAAP net loss and comprehensive loss of $20.6 million in the prior year period. Adjusted EBITDA* loss was $19.7 million compared to an adjusted EBITDA loss of $16.1 million in the prior year period. Cash and cash equivalents totaled $175 million as of October 31, 2025. The above cash and cash equivalents balance does not include the $148 million of net proceeds Kestra received from an underwritten public offering of 6.9 million common shares, which closed on December 4, 2025.   *Adjusted EBITDA is a non-GAAP financial measure. See “Use of Non-GAAP Financial Measures” below for additional information. A reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure is included in this press release. Fiscal Year 2026 Revenue GuidanceKestra is increasing its FY26 revenue guidance to $91 million, which would represent growth of 52% compared to FY25. This compares to prior FY26 revenue guidance of $88 million and initial FY26 guidance of $85 million. Webcast and Conference CallKestra will host a conference call today at 4:30 p.m. ET to discuss financial results. A live and archived webcast of the event will be available in the “Events” section of the investor relations website. Use of Non-GAAP Financial MeasuresThis press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Kestra’s financial measures presented in this press release that are calculated and presented in accordance with GAAP.  Adjusted EBITDA, which is calculated as net income (loss), as adjusted to exclude other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense, share-based compensation expense, and non-recurring new public company costs, is presented because management believes it allows investors to view the Company’s performance in a manner similar to the method used by management to evaluate the Company’s performance for both strategic and annual operating planning. Management believes that in order to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of Adjusted EBITDA, in addition to considering the Company’s GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of our ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare our period-over-period results.  The non-GAAP financial measures used by Kestra may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Kestra’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of Adjusted EBITDA reported in this press release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA” later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Forward-Looking StatementsExcept where otherwise noted, the information contained in this press release is as of December 11, 2025. Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Kestra’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; risks and uncertainties related to market conditions; and other risks and uncertainties, including those described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended April 30, 2025 and other filings filed or to be filed with the U.S. Securities and Exchange Commission (“SEC”). These filings, when made, are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.  KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share amounts)(unaudited)  Three Months Ended October 31,  Six Months Ended October 31,  2025  2024  2025  2024             Revenue$22,565  $14,710  $41,937  $27,492 Cost of revenue 11,141   8,880   21,661   17,462 Gross profit 11,424   5,830   20,276   10,030 Operating expenses:           Research and development 4,878   3,509   8,878   6,913 Selling, general and administrative 38,301   21,455   72,029   40,682 Total operating expenses 43,179   24,964   80,907   47,595 Loss from operations (31,755)  (19,134)  (60,631)  (37,565)Other expense (income):           Interest expense 1,901   2,317   3,814   4,191 Interest income (1,796)  (878)  (3,962)  (915)Other expense (income) 891   40   (1,939)  88 Net loss before provision for income taxes (32,751)  (20,613)  (58,544)  (40,929)Provision for income taxes 34   8   67   15 Net loss and comprehensive loss (32,785)  (20,621)  (58,611)  (40,944)Net loss attributable to non-controlling interest —   (253)  —   (692)Net loss and comprehensive loss attributable to Kestra Medical Technologies, Ltd. (32,785)  (20,368)  (58,611)  (40,252)Less: Undeclared preferred stock dividends —   3,323   —   5,706 Net loss attributable to common shareholders, basic and diluted$(32,785) $(23,691) $(58,611) $(45,958)            Net loss per share attributable to common shareholders, basic and diluted$(0.64) $(1.19) $(1.14) $(2.31)Weighted-average shares of common shares outstanding, basic and diluted 51,376,278   19,885,382   51,340,438   19,885,382  RECONCILIATION OF GAAP NET LOSS AND COMPREHENSIVE LOSS TO ADJUSTED EBITDA (in thousands)(unaudited)  Three Months Ended October 31,  Six Months Ended October 31,  2025  2024  2025  2024             GAAP Net loss and comprehensive loss$(32,785) $(20,621) $(58,611) $(40,944)Non-GAAP Adjustments:           Interest expense 1,901   2,317   3,814   4,191 Interest income (1,796)  (878)  (3,962)  (915)Other expense (income) 891   40   (1,939)  88 Provision for income taxes 34   8   67   15 Depreciation expense 2,372   1,869   4,401   4,244 Share-based compensation expense 8,653   1,122   13,232   1,499 Non-recurring expenses 1,048   —   3,914   — Adjusted EBITDA$(19,682) $(16,143) $(39,084) $(31,822) KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts)(unaudited)  October 31,  April 30,  2025  2025       Assets     Current assets     Cash and cash equivalents$175,424  $237,595 Accounts receivable, net 10,413   8,081 Disposable medical equipment supplies 6,918   6,572 Prepaid expenses and other current assets 2,659   3,080 Total current assets 195,414   255,328       Right-of-use assets 1,960   2,078 Deposits 1,858   2,021 Restricted cash 334   334 Property and equipment, net 45,932   34,830 Other long-term assets 1,203   1,153 Total assets$246,701  $295,744       Liabilities and Shareholders’ Equity     Current liabilities     Accounts payable$20,209  $23,961 Accrued liabilities 15,494   13,829 Operating lease liabilities, current portion 53   187 Total current liabilities 35,756   37,977       Operating lease liabilities, net of current portion 2,874   3,026 Warrant liabilities 1,977   8,097 Other long-term liabilities 140   140 Long-term debt, net 41,873   41,098 Total liabilities 82,620   90,338       Commitments and contingencies           Shareholders’ equity           Common shares, $1.00 par value; 100,000,000 shares authorized as of October 31, 2025 and April 30, 2025; 51,449,053 issued and outstanding as of October 31, 2025 and 51,348,656 shares issued and outstanding as of April 30, 2025 51,449   51,349 Additional paid-in capital 691,492   674,306 Accumulated deficit (578,860)  (520,249)Total shareholders’ equity 164,081   205,406 Total liabilities and shareholders’ equity$246,701  $295,744  KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)(unaudited)  Six Months Ended October 31,  2025  2024 Cash flows from operating activities     Net loss$(58,611) $(40,944)Adjustments to reconcile net loss to net cash used in operating activities:     Depreciation and amortization 4,401   4,244 Loss on disposal of property and equipment 560   580 Reserve for lost equipment and supplies 901   477 Provision for uncollectible accounts receivable 1,150   1,074 Interest paid-in-kind —   467 Amortization of debt discounts and issuance costs 937   861 Share-based compensation expense 13,232   1,499 Non-cash lease expense 148   242 Change in fair value of warrant liabilities (2,065)  — Changes in operating assets and liabilities:     Disposable medical equipment supplies (596)  (1,117)Prepaid expenses and other current assets 953   (53)Accounts receivable (3,482)  (4,470)Accounts payable (2,372)  (345)Accrued liabilities 520   1,786 Operating lease liabilities (313)  124 Other long-term assets 20   20 Net cash used in operating activities (44,617)  (35,555)Cash flows from investing activities     Purchases of property and equipment (15,431)  (11,484)Deposits for medical rental equipment (338)  (197)Refund of deposits for medical rental equipment: 117   227 Net cash used in investing activities (15,652)  (11,454)Cash flows from financing activities     Proceeds from issuance of redeemable preferred stock —   103,400 Proceeds from issuance of stock to non-controlling interest —   17,100 Deemed dividend for payments to third party on behalf of shareholder —   (1,598)Payment of equity issuance costs: (1,902)  (3,224)Net cash provided by (used in) financing activities (1,902)  115,678 Net increase (decrease) in cash, cash equivalents and restricted cash (62,171)  68,669 Cash, cash equivalents and restricted cash     Beginning of period 237,929   8,583 End of period$175,758  $77,252 Reconciliation of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheets     Cash and cash equivalents$175,424  $76,918 Restricted cash: 334   334 Cash, cash equivalents and restricted cash$175,758  $77,252 Non-cash investing and financing activities:     Purchases of property and equipment in accrued liabilities and accounts payable$8,313   7,914 Exercise of liability classified warrant 4,055   — Supplemental disclosure of cash flow information     Income taxes paid (refunds received)$(18) $43 Interest paid 2,846   2,451  CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced an underwritten public offering of 5,500,000 common shares. Kestra is offering these shares pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (“SEC”). Kestra also intends to grant the underwriters a 30-day option to purchase up to an additional 825,000 common shares at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed or as to the actual size or terms of the offering. Kestra intends to use the proceeds to support sales and marketing activities, to drive ongoing commercialization, to further fund our research and development and clinical studies and for working capital and general corporate purposes. All of the common shares are being offered by Kestra. BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs & Co. LLC and Wells Fargo Securities are acting as bookrunners for the proposed offering. The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com; Piper Sandler, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attention: Prospectus Department, by telephone at 800-747-3924 or by email at prospectus@psc.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Cautionary Statements Regarding Forward-Looking Information Except where otherwise noted, the information contained in this press release is as of December 1, 2025. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, Kestra’s expectations regarding the consummation, timing and size of the offering and the grant of the option to purchase additional shares to the underwriters. Statements in this press release that express a belief, expectation or intention, as well as those that are not based on historical fact, as forward-looking statements. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially from those currently anticipated include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the offering and other risks and uncertainties described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2025 filed with the SEC on July 17, 2025, and in other periodic reports filed by the Company with the SEC. These filings, when made, are available on the Investor Relations section of our website and on the SEC’s website at https://sec.gov/. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. About Kestra Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. CONTACT: Investor contact
Neil Bhalodkar 
neil.bhalodkar@kestramedical.com 

KIRKLAND, Wash., Oct. 07, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Timothy Moran as Chief Business Officer, effective November 3. In this role, Mr. Moran will oversee business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management. “I am pleased to welcome Tim as our Chief Business Officer,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “With extensive expertise in cardiac and heart failure innovation, Tim is well positioned to join Kestra at this important stage in our commercial ramp. We expect he will help Kestra advance our payor and provider partnerships, accelerate adoption of the Cardiac Recovery System® platform, and further expand and develop our business strategy.” Mr. Moran is a seasoned operating executive who brings over 25 years of experience in medtech organizations to his new role at Kestra. Most recently, he served as President and Chief Executive Officer at Avertix Medical where he led the launch of a first-to-market implantable cardiac device for the detection of acute coronary syndrome events. Prior to that, he was the Chief Executive Officer of Motus GI Holdings, a medical technology company focused on improving endoscopic outcomes and experiences. “I’m excited to join Kestra at such a pivotal time in the organization’s growth,” said Mr. Moran. “Kestra’s commitment to innovation and patient protection aligns with my passion for building organizations that drive meaningful impact in healthcare. I look forward to working with our payor partners, physicians, and the Kestra team to extend the reach of the ASSURE® WCD and the broader Cardiac Recovery System platform so more patients can benefit from proven protection and comprehensive recovery support.” About Kestra Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.  CONTACT: Media contact 
Rhiannon Pickus 
rhiannon.pickus@kestramedical.com 

Investor contact 
Neil Bhalodkar 
neil.bhalodkar@kestramedical.com 

KIRKLAND, Wash., Sept. 17, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Elizabeth Kwo, M.D. as an independent director to its board following her election at the company’s annual general meeting of shareholders held earlier this month. “I am pleased to welcome Dr. Kwo to the Kestra board of directors,” said Brian Webster, President and CEO of Kestra Medical Technologies. “As a physician, healthcare executive, and entrepreneur, she brings extensive experience building and scaling digital health platforms and advancing data-driven care models to improve patient outcomes. Her expertise and perspective will be invaluable as we accelerate adoption of our lifesaving Cardiac Recovery System platform.” Dr. Kwo currently serves as Chief Commercial Officer of Everly Health, Inc, a diagnostics-driven digital healthcare company. She previously served as Deputy Chief Clinical Officer for Anthem, VP and GM of Provider Networks at American Well, and Entrepreneur in Residence at Harvard Medical School’s Office of Technology Development. She has also founded multiple venture-backed companies, including the educational platform New Pathway and digital healthcare company InfiniteMD. Dr. Kwo is board certified in preventive care and occupational medicine and remains active as a practicing physician. She earned her M.D. from Harvard Medical School, an M.P.H. from the Harvard T.H. Chan School of Public Health, an M.B.A. from Harvard Business School, and a B.A. from Stanford University. “I’m honored to join Kestra’s board of directors at such a pivotal time,” said Dr. Kwo. “Kestra’s commitment to protecting patients through innovation in cardiac recovery deeply resonates with me. I look forward to contributing my experience in digital health and care-model innovation to help advance the company’s mission and expand its impact for patients and providers.” About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com. CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com

KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial Highlights Generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period.Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period.Increased FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. “We had a strong start to fiscal 2026, with our sustained commercial momentum generating revenue growth of over 50% in the first quarter,” said Brian Webster, President and CEO. “We also continued to make progress on several key operational objectives, including growing the commercial organization, enhancing our revenue cycle management capabilities, and expanding gross margin. As we progress on our journey to category leadership, we remain focused on both market share capture and growing the wearable defibrillator market, while executing on our commitments to patients and their prescribers.” First Quarter Fiscal 2026 Financial Results Total revenue was $19.4 million, an increase of 52% compared to the prior year period. 4,205 prescriptions were written for the ASSURE® system, an increase of 51% compared to the prior year period.Revenue growth was driven by higher market share with existing customers and activation of new accounts. Revenue also benefited from a higher mix of in-network patients and improvements in revenue cycle management capabilities. Gross profit was $8.9 million compared to $4.2 million in the prior year period. Gross margin expanded to 45.7% compared to 32.9% in the prior year period, driven by volume leverage and a higher mix of in-network patients. GAAP operating expenses were $37.7 million and included $2.9 million of non-recurring new public company costs. GAAP operating expenses were $22.6 million in the prior year period. Excluding non-recurring new public company costs and share-based compensation expense, operating expenses were $30.3 million in Q1 FY26. The increase was attributable to growth in expenses related to commercial and revenue cycle resources. GAAP net loss and comprehensive loss was $25.8 million compared to GAAP net loss and comprehensive loss of $20.3 million in the prior year period. Adjusted EBITDA* loss was $19.4 million compared to an adjusted EBITDA loss of $15.7 million in the prior year period. Cash and cash equivalents totaled $201.2 million as of July 31, 2025. *Adjusted EBITDA is a non-GAAP financial measure. See “Use of Non-GAAP Financial Measures” below for additional information. A reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure is included in this press release. Fiscal Year 2026 Revenue GuidanceKestra is increasing its FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. This compares to prior FY26 revenue guidance of $85 million. Webcast and Conference CallKestra will host a conference call today at 4:30 p.m. ET to discuss first quarter fiscal 2026 financial results. A live and archived webcast of the event will be available in the “Events” section of the investor relations website. Use of Non-GAAP Financial MeasuresThis press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Kestra’s financial measures presented in this press release that are calculated and presented in accordance with GAAP. Adjusted EBITDA, which is calculated as net income (loss), as adjusted to exclude other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense, share-based compensation expense, and non-recurring new public company costs, is presented because management believes it allows investors to view the Company’s performance in a manner similar to the method used by management to evaluate the Company’s performance for both strategic and annual operating planning. Management believes that in order to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of Adjusted EBITDA, in addition to considering the Company’s GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of our ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare our period-over-period results. The non-GAAP financial measures used by Kestra may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Kestra’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of Adjusted EBITDA reported in this press release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA” later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Forward-Looking StatementsExcept where otherwise noted, the information contained in this press release is as of September 11, 2025. Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Kestra’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended April 30, 2025 and other filings filed or to be filed with the U.S. Securities and Exchange Commission (“SEC”). These filings, when made, are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com. KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(in thousands, except share and per share amounts)(unaudited)   Three Months Ended July 31,   2025  2024        Revenue $19,371  $12,782 Cost of revenue  10,520   8,582 Gross profit  8,851   4,200 Operating expenses:      Research and development  4,001   3,404 Selling, general and administrative  33,728   19,227 Total operating expenses  37,729   22,631 Loss from operations  (28,878)  (18,431)Other expense (income):      Interest expense  1,912   1,874 Interest income  (2,167)  (37)Other expense (income)  (2,830)  48 Net loss before provision for income taxes  (25,793)  (20,316)Provision for income taxes  33   7 Net loss and comprehensive loss  (25,826)  (20,323)Net loss attributable to non-controlling interest  —   (439)Net loss and comprehensive loss attributable to Kestra Medical Technologies, Ltd.  (25,826)  (19,884)Less: Undeclared preferred stock dividends  —   2,383 Net loss attributable to common shareholders, basic and diluted $(25,826) $(22,267)       Net loss per share attributable to common shareholders, basic and diluted $(0.50) $(1.12)Weighted-average shares of common shares outstanding, basic and diluted  51,304,599   19,885,382  RECONCILIATION OF GAAP NET LOSS AND COMPREHENSIVE LOSS TO ADJUSTED EBITDA(in thousands)(unaudited)   Three Months Ended July 31,   2025  2024        GAAP Net loss and comprehensive loss $(25,826) $(20,323)Non-GAAP Adjustments:      Interest expense  1,912   1,874 Interest income  (2,167)  (37)Other expense (income)  (2,830)  48 Provision for income taxes  33   7 Depreciation expense  2,028   2,375 Share-based compensation expense  4,579   377 Non-recurring new public company costs  2,866   — Adjusted EBITDA $(19,405) $(15,679) KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts)(unaudited)   July 31,  April 30,   2025  2025        Assets      Current assets      Cash and cash equivalents $201,214  $237,595 Accounts receivable, net  9,246   8,081 Disposable medical equipment supplies  6,802   6,572 Prepaid expenses and other current assets  3,429   3,080 Total current assets  220,691   255,328        Right-of-use assets  2,046   2,078 Deposits  1,787   2,021 Restricted cash  334   334 Property and equipment, net  40,376   34,830 Other long-term assets  1,062   1,153 Total assets $266,296  $295,744        Liabilities and Shareholders’ Equity      Current liabilities      Accounts payable $18,570  $23,961 Accrued liabilities  13,650   13,829 Operating lease liabilities, current portion  36   187 Total current liabilities  32,256   37,977        Operating lease liabilities, net of current portion  3,067   3,026 Warrant liabilities  5,188   8,097 Other long-term liabilities  140   140 Long-term debt, net  41,486   41,098 Total liabilities  82,137   90,338        Commitments and contingencies             Shareholders’ equity             Common shares, $1.00 par value; 100,000,000 shares authorized as of July 31, 2025 and April 30, 2025; 51,348,656 shares issued and outstanding as of July 31, 2025 and April 30, 2025  51,349   51,349 Additional paid-in capital  678,885   674,306 Accumulated deficit  (546,075)  (520,249)Total shareholders’ equity  184,159   205,406 Total liabilities and shareholders’ equity $266,296  $295,744 CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

KIRKLAND, Wash., July 15, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the fourth quarter and fiscal year ended April 30, 2025. Financial Highlights Reported revenue of $17.2 million in Q4 FY25, an increase of 71% compared to the prior year period.Reported revenue of $59.8 million in FY25, an increase of 115% compared to FY24.Generated gross margin of 44.3% in Q4 FY25 compared to 13.9% in the prior year period.Generated gross margin of 40.5% in FY25 compared to 1.3% in FY24.Initiated FY26 revenue guidance of $85 million, an increase of 42% compared to FY25. “We capped an exciting year for Kestra with a very strong finish to our fiscal 2025. This quarter’s financial results reflect accelerating demand for our best-in-class cardiac recovery system as we continue to benefit from heightened prescriber awareness and the overwhelmingly positive experience patients are having with the ASSURE® system,” said Brian Webster, President and CEO. “In addition to our commercial execution, we are encouraged by the meaningful improvement in our gross margin, a result of the attractive unit economics and positive leverage inherent in our business model.” Mr. Webster continued, “In fiscal year 2025, the ASSURE® system protected thousands of patients from sudden cardiac arrest, a testament to the dedication of our mission-driven team. We also made progress on several key operational objectives, including significant growth of our commercial organization and planned enhancements to our revenue cycle capabilities. We remain confident that our commitment to innovation and intense focus on prescriber and patient support will drive market expansion and advance Kestra’s pursuit of market leadership.” Fourth Quarter Fiscal 2025 Financial Results Total revenue was $17.2 million in Q4, an increase of 71% compared to the prior year period. 3,903 prescriptions were written for the ASSURE® system in Q4, an increase of 43% compared to the prior year period.Revenue growth was driven by a higher share of wallet with existing customers and activation of new accounts. Revenue also benefited from a higher mix of in-network patients and improvements in revenue cycle management capabilities. Gross profit was $7.6 million in Q4 compared to $1.4 million in the prior year period. Gross margin expanded to 44.3% in Q4 compared to 13.9% in the prior year period, driven by volume leverage and a higher mix of in-network patients. GAAP operating expenses were $55.8 million in Q4 and included $22.3 million of share-based compensation expense and $3.8 million of professional services expenses related to the company’s IPO. GAAP operating expenses were $21.7 million in the prior year period. As a result of the company’s IPO in March, share-based compensation expense in Q4 included one-time impacts from the accelerated vesting of incentive units and the issuance of stock options to Kestra team members.Excluding share-based compensation and professional services expenses related to the IPO, operating expenses were $29.7 million in Q4 compared to $21.4 million in the prior year period. The increase was attributable to growth in expenses related to commercial and revenue cycle resources. GAAP net loss and comprehensive loss was $51.1 million in Q4 compared to GAAP net loss and comprehensive loss of $22.3 million in the prior year period. Adjusted EBITDA* loss was $20.3 million in Q4 compared to an adjusted EBITDA loss of $16.5 million in the prior year period. Cash and cash equivalents totaled $237.6 million as of April 30, 2025. Fiscal Year 2025 Financial Results Total revenue was $59.8 million in FY25, an increase of 115% compared to FY24. 13,193 prescriptions were written for the ASSURE® system in FY25, an increase of 72% compared to FY24. Gross profit was $24.2 million in FY25 compared to $0.4 million in FY24. Gross margin expanded to 40.5% in FY25 compared to 1.3% in FY24. GAAP operating expenses were $130.6 million in FY25 compared to $85.4 million in FY24. Excluding share-based compensation and professional services expenses related to the IPO, operating expenses were $100.6 million in FY25 compared to $83.9 million in FY24. GAAP net loss and comprehensive loss was $113.8 million in FY25 compared to GAAP net loss and comprehensive loss of $94.1 million in FY24. Adjusted EBITDA* loss was $68.4 million in FY25 compared to an Adjusted EBITDA loss of $72.0 million in FY24. *Adjusted EBITDA is a non-GAAP financial measure. See “Use of Non-GAAP Financial Measures” below for additional information. A reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure is included in this press release. Fiscal Year 2026 Revenue GuidanceKestra expects revenue of $85 million in FY26, an increase of 42% compared to FY25. Webcast and Conference CallKestra will host a conference call today at 4:30 p.m. ET to discuss fourth quarter and fiscal year 2025 financial results. A live and archived webcast of the event will be available in the “Events” section of the investor relations website. Use of Non-GAAP Financial MeasuresThis press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Kestra’s financial measures presented in this press release that are calculated and presented in accordance with GAAP. Adjusted EBITDA, which is calculated as net income (loss), as adjusted to exclude other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense, share-based compensation expense, and expenses related to Kestra’s initial public offering, is presented because management believes it allows investors to view the Company’s performance in a manner similar to the method used by management to evaluate the Company’s performance for both strategic and annual operating planning. Management believes that in order to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of Adjusted EBITDA, in addition to considering the Company’s GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of our ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare our period-over-period results. The non-GAAP financial measures used by Kestra may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Kestra’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of Adjusted EBITDA reported in this press release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA” later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Forward-Looking StatementsExcept where otherwise noted, the information contained in this press release is as of July 15, 2025. Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Kestra’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading “Risk Factors” in our Registration Statement on Form S-1 and other filings filed or to be filed with the U.S. Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the fiscal year ended April 30, 2025. These filings, when made, are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com. KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts)(unaudited)  April 30,  2025  2024       Assets     Current assets     Cash and cash equivalents$237,595  $8,249 Accounts receivable, net 8,081   1,998 Disposable medical equipment supplies 6,572   3,290 Prepaid expenses and other current assets 3,080   1,370 Total current assets 255,328   14,907       Right-of-use assets 2,078   2,286 Deposits 2,021   1,710 Restricted cash 334   334 Property and equipment, net 34,830   26,105 Other long-term assets 1,153   607 Total assets$295,744  $45,949       Liabilities, Redeemable Preferred Stock and Shareholders’ Equity (Deficit)     Current liabilities     Accounts payable$23,961  $23,892 Accrued liabilities 13,829   9,079 Operating lease liabilities, current portion 187   — Total current liabilities 37,977   32,971       Operating lease liabilities, net of current portion 3,026   2,633 Warrant liabilities 8,097   — Other long-term liabilities 140   76 Long-term debt, net 41,098   42,536 Total liabilities 90,338   78,216       Commitments and contingencies           Redeemable preferred stock, $0.01 par value; 0 and 5,000,000 shares authorized as of April 30, 2025 and April 30, 2024, respectively; 0 and 177,110 shares issued and outstanding as of April 30, 2025 and April 30, 2024, respectively —   177,110       Shareholders’ equity (deficit)           Common stock, $0.01 par value; 5,000,000 shares authorized as of April 30, 2024; 105,808 shares issued and outstanding as of April 30, 2024 —   1 Common shares, $1.00 par value; 100,000,000 shares authorized as of April 30, 2025; 51,348,656 shares issued and outstanding as of April 30, 2025 51,349   — Additional paid-in capital 674,306   197,057 Accumulated deficit (520,249)  (406,435)Total shareholders’ equity (deficit) 205,406   (209,377)Total liabilities and shareholders’ equity (deficit)$295,744  $45,949  KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share amounts)(unaudited)  Three Months Ended April 30,  Year Ended April 30,  2025  2024  2025  2024             Revenue$17,233  $10,054  $59,815  $27,814 Cost of revenue 9,600   8,657   35,605   27,452 Gross profit 7,633   1,397   24,210   362 Operating expenses:           Research and development 5,386   3,821   15,652   15,490 Selling, general and administrative 50,459   17,925   114,936   69,935 Total operating expenses 55,845   21,746   130,588   85,425 Loss from operations (48,212)  (20,349)  (106,378)  (85,063)Other expense (income):           Interest expense 1,760   1,935   7,734   6,230 Interest income (1,656)  —   (3,199)  — Other expense 2,693   27   2,766   2,803 Net loss before provision for income taxes (51,009)  (22,311)  (113,679)  (94,096)Provision for income taxes 102   (27)  135   24 Net loss and comprehensive loss (51,111)  (22,284)  (113,814)  (94,120)Less: Undeclared preferred stock dividends 3,291   1,994   12,321   6,721 Net loss attributable to common shareholders, basic and diluted$(54,402) $(24,278) $(126,135) $(100,841)            Net loss per share attributable to common shareholders, basic and diluted$(2.21) $(1.22) $(5.13) $(5.07)Weighted-average shares of common shares outstanding, basic and diluted 24,583,745   19,885,382   24,583,745   19,885,382  RECONCILIATION OF GAAP NET LOSS AND COMPREHENSIVE LOSS TO ADJUSTED EBITDA (in thousands)(unaudited)  Three Months Ended April 30,  Year Ended April 30,  2025  2024  2025  2024             GAAP Net loss and comprehensive loss$(51,111) $(22,284) $(113,814) $(94,120)Non-GAAP Adjustments:           Interest expense 1,760   1,935   7,734   6,230 Interest income (1,656)  —   (3,199)  — Other expense 2,693   27   2,766   2,803 Provision for income taxes 102   (27)  135   24 Depreciation expense 1,836   3,502   7,968   11,560 Share-based compensation expense 22,313   389   24,271   1,488 IPO expense 3,809   —   5,736   — Adjusted EBITDA$(20,254) $(16,458) $(68,403) $(72,015) CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

KIRKLAND, Wash., July 01, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that it will report fourth quarter and fiscal year 2025 financial results on Tuesday, July 15. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the “Events” section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com. CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com 

KIRKLAND, Wash., June 23, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that the company will be added to the Russell 3000® Index, with automatic inclusion in the Russell 2000® Index, effective after the U.S. market close on June 27. The annual reconstitution of the Russell indexes captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index results in automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index and the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against the Russell U.S. indexes. “We are honored to be included in the Russell indexes,” said Brian Webster, President and CEO of Kestra Medical Technologies. “The inclusion of Kestra in the Russell indexes following our March 2025 initial public offering is a significant milestone in our public company journey. As we continue to expand our presence across markets, we remain focused on protecting more patients at risk of sudden cardiac arrest and creating long-term value for our shareholders.” About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com. CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com